Effects of Chromium Supplementation on Glycemic Control in Patients with Type 2 Diabetes
|
Seyed Peyman Payami , Sara Saffarian , Atefeh Hasanzadeh |
Diabetes Research Center, Ahvaz Jundishapur University of medical Sciences , Peyman_Payami@ajums.ac.ir |
|
Abstract: (11920 Views) |
Introduction: Although some studies show that Chromium picolinate supplementation can improve glycemic control in type 2, diabetic patients, information available in this regard is conflicting. The aim of this study is to determine the effect of chromium picolinate on glycemic control in subjects with type 2 diabetes. Materials and Methods: In this the randomized, double blind placebo controlled clinical trial, 40 patients with type 2 diabetes were investigated. They were divided into two groups (n=20 each), the randomized and placebo groups, the former receiving 200 microgram chromium as chromium picolinate (n=20) for 3 months. Body composition, lipid profile, and glycemic control were determined at baseline and at the end of study. Results: Subjects randomized to chromium picolinate, as compared to the placebo group, had a significant decrease in HbA1C (-41%, P=0.007vs. 0.12%, P = 0.054) and FBS levels (-22.05%, P = .001 vs. -1.35%, P= .859). There was no improvement in body composition and lipid profiles of subjects randomized to chromium picolinate, compared to controls. Conclusion: Results of this study suggest that chromium picolinate supplementation in subjects with type 2 diabetes can improve glucose control but it has no effect on body composition and lipid profiles. |
|
Keywords: Diabetes type 2, Chromium Picolinate, HbA1C |
|
Full-Text [PDF 267 kb]
(4756 Downloads)
|
Type of Study: Original |
Subject:
Endocrinology Received: 2011/06/26 | Accepted: 2012/03/4 | Published: 2012/09/15
|
|
|
|
|
Add your comments about this article |
|
|